Skip to content
The Policy VaultThe Policy Vault

Xeljanz XR — Medical Mutual

Psoriatic Arthritis

Initial criteria

  • Patient is age ≥ 18 years; AND
  • Patient has had a 3-month trial of at least one tumor necrosis factor inhibitor OR patient has tried at least one tumor necrosis factor inhibitor but was unable to tolerate a 3-month trial; AND
  • The medication will be used in combination with methotrexate or another conventional synthetic DMARD, unless contraindicated; AND
  • The medication is prescribed by or in consultation with a rheumatologist or a dermatologist.

Reauthorization criteria

  • Patient has been established on therapy for at least 6 months; AND
  • The medication will be used in combination with methotrexate or another conventional synthetic DMARD, unless contraindicated; AND
  • When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline OR compared with baseline, patient experienced an improvement in at least one symptom such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths.

Approval duration

initial 6 months, reauth 1 year